1 / 16

HERHANGİ BİR ÇIKAR ÇATIŞMASI YOKTUR…

HERHANGİ BİR ÇIKAR ÇATIŞMASI YOKTUR…. Serum soluble TRAIL levels in patients with severe persistent allergic asthma: its relation to Omalizumab treatment. DR.ARZU DİDEM YALÇIN. Apoptosis. Mitosis. . . Artışı da Azalışı da. ÇOK HÜCRELİ CANLILARDA HÜCRE SAYISININ KONTROLÜ.

nishan
Download Presentation

HERHANGİ BİR ÇIKAR ÇATIŞMASI YOKTUR…

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HERHANGİ BİR ÇIKAR ÇATIŞMASI YOKTUR…

  2. Serum soluble TRAIL levels in patients with severe persistent allergic asthma: its relation to Omalizumab treatment DR.ARZU DİDEM YALÇIN

  3. Apoptosis Mitosis   Artışı da Azalışı da ÇOK HÜCRELİ CANLILARDA HÜCRE SAYISININ KONTROLÜ

  4. İç (mitokondri) ve dış (DR) apopitotik sinyal yolları. İki sistem arasında etkileşim vardır.

  5. Apoptosis’in Başlatılması(Ölüm Reseptörleri)

  6. Mitokondriyal Yol Ölüm Resreptörleri Yolu seramid diğerleri oksidanlar FasL Fas/Apo1 /CD95 DNA hasarı D D Bcl-2 D D D FADD DISC Procaspase 8 Apaf -1 BID Procaspase 9 Cytochrome c Procaspase 3 Caspase 8 Apaf -1 dATP dATP Caspase 3 Hücresel Hedefler Caspase 9 apoptozom Hengartner, M.O. 2000. Nature. 407:770. Green, D. and Kroemer, G. 1998. Trends Cell Biol. 8:267. Memeli Hücresindeki Major Apoptotik Yollar

  7. TRAIL-R1/R2 HÜCRE YÜZEYİ PROKASPAZ-8 / 10 FLIP FLIP FADD?, TRADD? KASPAZ-8 / 10 PROKASPAZ-3 KASPAZ-3 DİĞER KASPAZLAR ? HÜCRE ÖLÜMÜ PARP KLİVAJI, DNA DEGRADASYONU TRAIL-R ARACILIKLI HÜCRE ÖLÜMÜ YOLAĞI

  8. Yalçın AD, Öncel S, Akcan A, Eravşar K, Polat HH, Terzioğlu E. Prevalance of allergic asthma, rhinitis and conjunctivitis in over 16 year old individuals in Antalya . Turkiye Klinikleri J Med Sci 2010; 30(3):888-94 Yalçın AD, Ozdemir L, Polat HH. Evaluation of the Patients receiving Allergen-specific Immunotheraphy In Antalya. 2011 (BMJ)

  9. Serum soluble TRAIL levels in patients with severe persistent allergic asthma: its relation to Omalizumab treatment Yalcin AD, Bisgin A, Cetinkaya R, Gumuslu S. Clinical efficacy of omalizumab in severe persistent asthma and co-morbid conditions. The American Journal of Case Reports, 2011; Yalçın AD. Clinical Efficacy And Side Effect Of Omalizumab .Brat Med Journal 2011; (in press) Yalçın AD, Bisgin A, Kargi A, Kose S, Terzioğlu E, Gorczynski RM. Efficacy of omalizumab and specific subcutane immunotherapy as a treatment modality in allergic asthmasAPAllergy and immunology(in press) Yalçın AD, Gorczynski RM ,et al.Total antioxidant capacity, hydrogen peroxide, malondialdehyde and total nitric oxide concentrations in patients with severe persistent allergic asthma: its relation to omalizumab treatment. American journal of Rhinology and allergy.American journal of Rhinology and Allergy. (in press) Omalizumab (trade name Xolair), a recombinant humanized monoclonal antibody to IgE, is recommended as one (new) option for the treatment of severe persistent allergic (IgE mediated) asthma .

  10. Serum soluble TRAIL levels in patients with severe persistent allergic asthma: its relation to Omalizumab treatment

  11. Serum soluble TRAIL levels in patients with severe persistent allergic asthma: its relation to Omalizumab treatment

  12. Serum soluble TRAIL levels in patients with severe persistent allergic asthma: its relation to Omalizumab treatment The results for patients in both groups were compared with those of healthy subjects. These data were analyzed using SPSS version 13.0 for Windows (SPSS Inc., Chicago, IL, USA). Independent two samples t-test were used for comparison of two intergroups. Wilcoxon's matched-pairs signed-rank test were used for comparison of two dependent intergroups. Serum sTRAIL levels in all individuals (patients and healthy controls) were measured by a sandwich enzyme-linked immunosorbent assay (Diaclone, France).

  13. Serum soluble TRAIL levels in patients with severe persistent allergic asthma: its relation to Omalizumab treatment

  14. TEŞEKKÜRLERarzu didem yalcin adidyal@yahoo.comProf.Dr.Reginald M GORCZYNSKI, BA, MD, PhD: Transplant Unit, Division of Cellular & Molecular Biology, Toronto Hospital, University Health Network, Toronto, ON, Canada.Assoc .Prof. Dr. Ramazan CETINKAYA, MD: Division of Nephrology, Antalya Education and Training HospitalProf. Saadet GUMUSLU, PhD: Department of Biochemistry, Akdeniz University Faculty of MedicineAssoc. Prof. Dr. Sukran KOSE, MD: Allergology and Clinical Immunology Unit, Izmir Tepecik Education and Training Hospital.Prof. Dr. Ender TERZIOGLU, MD: Department of Allergology and Clinical Immunology, Akdeniz University Faculty of Medicine.

More Related